Earn CME: https://naccme.com/program/7331
In this presentation from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Mojtaba Akhtari discusses a patient case to examine whether transplant, conventional therapy, or novel targeted is most appropriate for the MRD+ patient subset and in what conditions.
© 2019 Imedex, an HMP Company
Advertisement